Targeting CD52 provides durable depletion of circulating CAR-T cells in a patient with BCMA-CAR-T cell-associated parkinsonism

This publication has 22 references indexed in Scilit:

• Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial
  The Lancet Oncology, 2026
• Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma
  Nature Communications, 2025
• Neurological complications of CAR T cell therapy for cancers
  Nature Reviews Neurology, 2025
• Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study
  The Lancet Rheumatology, 2025
• Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee
  The Lancet Oncology, 2025
• Current understanding and management of CAR T cell-associated toxicities
  Nature Reviews Clinical Oncology, 2024
• Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
  New England Journal of Medicine, 2023
• Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies
  Blood Cancer Journal, 2022
• Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy
  Nature Medicine, 2021
• Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
  The Lancet, 2021